Market Update: Eli Lilly & Company (NYSE:LLY) – Type 2 diabetes: findings presented from retrospective analysis of pooled data examining linagliptin in African-American adults

[PR Newswire] – RIDGEFIELD, Conn. and INDIANAPOLIS, May 15, 2014 /PRNewswire/ — Data from a retrospective pooled analysis of eight phase III trials (two 18-week and six 24-week) of linagliptin 5 mg once-daily, . . . → Read More: Market Update: Eli Lilly & Company (NYSE:LLY) – Type 2 diabetes: findings presented from retrospective analysis of pooled data examining linagliptin in African-American adults Similar Articles: Stock Update: Eli Lilly & Company (NYSE:LLY) – Ready to go? The importance of advance planning: Lilly Diabetes and the American College of Endocrinology (ACE) help people with diabetes prep for emergencies Market Update (NYSE:LLY): Lilly Declares Second-Quarter 2014 Dividend Company Update – Bristol-Myers Squibb Company (NYSE:BMY) – Xigduo™ (dapagliflozin and metformin hydrochloride) receives positive CHMP opinion in the European Union for the treatment of type 2 diabetes